Boston, Massachusetts, United States The main department of described VC is located in the Boston. The company was established in North America in United States.
The common things for fund are deals in the range of 50 - 100 millions dollars. The higher amount of exits for fund were in 2017. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 investment rounds annually. Opposing the other organizations, this Clough Capital Partners works on 54 percentage points more the average amount of lead investments.
The overall number of key employees were 2.
The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Clough Capital Partners, startups are often financed by Kleiner Perkins, DAG Ventures, OrbiMed. The meaningful sponsors for the fund in investment in the same round are Quan Capital, Qiming Venture Partners, OrbiMed. In the next rounds fund is usually obtained by Novartis.
The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline ARMO BioSciences, Arcellx, Elcelyx Therapeutics Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular fund investment industries, there are Therapeutics, Genetics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Related Funds
| Fund Name | Location |
| Alibaba Taiwan Entrepreneurs Fund II | - |
| Aris Prime Partner | Central, Central Region, Singapore |
| CAP-idea | California, San Francisco, United States |
| Chengdu Luxin Jingrong Equity Investment Fund Management | Chengdu, China, Sichuan |
| Corp Strategics | - |
| Federal-Mogul Motorparts | - |
| Galen Partners | Connecticut, Stamford, United States |
| GfK | Bayern, Germany, Nuremberg |
| Inception Venture Capital Investments | - |
| Kaltroco LTD | - |
| Kopin Corporation | Massachusetts, United States, Westborough |
| LightbayCapital | California, Los Angeles, United States |
| Macro Vision Capital | Beijing, Beijing, China |
| Massachusetts Capital Resource Company | Boston, Massachusetts, United States |
| MKI | Seoul, Seoul-t'ukpyolsi, South Korea |
| Prometheus Blockchain Application Union | Beijing, Beijing, China |
| Sovereign's Capital | North Carolina, Raleigh, United States |
| SunBridge | Japan, Kanagawa Prefecture, Kawasaki |
| Yuema Investment Management | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Amunix | $117M | 04 Mar 2021 | Mountain View, California, United States | ||
Checkmate Pharmaceuticals | $85M | 10 Jun 2020 | Cambridge, Massachusetts, United States | ||
Arcellx | $85M | 03 Oct 2019 | Maryland, United States | ||
Amphivena Therapeutics | $62M | 24 Sep 2019 | South San Francisco, California, United States | ||
ARMO BioSciences | $67M | 29 Aug 2017 | Redwood City, California, United States | ||
Sienna Biopharmaceuticals | $40M | 24 Apr 2017 | California, United States | ||
CRISPR Therapeutics | $38M | 24 Jun 2016 | Cambridge, Massachusetts, United States |
– Amunix Pharmaceuticals from South San Francisco develops masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers.
– Series B $117m round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management and existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.
– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Amunix | $117M | 04 Mar 2021 | Mountain View, California, United States | ||
Checkmate Pharmaceuticals | $85M | 10 Jun 2020 | Cambridge, Massachusetts, United States | ||
Arcellx | $85M | 03 Oct 2019 | Maryland, United States | ||
Amphivena Therapeutics | $62M | 24 Sep 2019 | South San Francisco, California, United States | ||
ARMO BioSciences | $67M | 29 Aug 2017 | Redwood City, California, United States | ||
Sienna Biopharmaceuticals | $40M | 24 Apr 2017 | California, United States | ||
CRISPR Therapeutics | $38M | 24 Jun 2016 | Cambridge, Massachusetts, United States |
